Sanofi’s multiple sclerosis drug flunks Phase 3 trial, faces another PDUFA delay

Sanofi reported that its BTK inhibitor which it said has blockbuster potential in multiple sclerosis hit setbacks in two different forms of the disease. The French drugmaker said tolebrutinib failed a ...